20/20 BioLabs to Host Virtual Investor Webinar on Thursday, February 26, 2026 at 2:00 p.m. Eastern Time

About this update from 20/20 Biolabs, Inc.

[{"type":"image","alt":"20/20 Biolabs Inc.","displaySize":"","headline":null,"caption":"20/20 Biolabs Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":244,"height":159,"url":"https://media.zenfs.com/en/globenewswire.com/d2abb3d4c13adceb39a31a2c97271190"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9sR3D0W2q_.DygCdr.xgmg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d2abb3d4c13adceb39a31a2c97271190","width":244,"height":159}},"lazy":false},{"type":"image","alt":"2020 BioLabs Nasdaq Tower","displaySize":"","headline":null,"caption":"2020 BioLabs Nasdaq Tower","className":"","disableSlideshowImg":false,"size":{"original":{"width":4068,"height":2712,"url":"https://media.zenfs.com/en/globenewswire.com/e5f05a17500f36cd58bccb6f7e5a1195"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PVJaNknCEiUbrwfSKtMi2A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e5f05a17500f36cd58bccb6f7e5a1195","width":960,"height":640},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/u.ZaBC07ylSUCOydm4dw0Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xNjAwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/e5f05a17500f36cd58bccb6f7e5a1195","width":1200,"height":800}}},{"type":"text","content":"","length":0,"tagName":"p"},{"type":"text","content":"GAITHERSBURG, Md., Feb. 20, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX), an early market leader in cutting-edge, AI-powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, announced today that it will hold a virtual investor webinar on Thursday, February 26, 2026 at 2:00 p.m. Eastern Time.","length":359,"tagName":"p"},{"type":"text","content":"20/20 BioLabs President and CEO Jonathan Cohen will host the webinar to discuss the company’s recent Nasdaq listing, OneTest™ for Cancer™ AI powered multi-cancer early detection (“MCED”) blood test, One Test for Longevity™ expected to be launched before the end February, ongoing initiatives, and upcoming milestones. A question-and-answer session will follow.","length":360,"tagName":"p"},{"type":"text","content":"Virtual Investor Webinar","length":24,"tagName":"p"},{"type":"text","content":"February 26, 20262:00 p.m. Eastern TimeWebcast and Presentation:https://us02web.zoom.us/webinar/register/WN_PC...

More updates from 20/20 Biolabs, Inc.